These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20843593)

  • 1. A policy case study of blood in Australia.
    Graves N; Clare G; Haines M; Bird R
    Soc Sci Med; 2010 Nov; 71(9):1677-82. PubMed ID: 20843593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery.
    van Hulst M; Bilgin YM; van de Watering LM; de Vries R; van Oers MH; Brand A; Postma MJ
    Transfus Med; 2005 Jun; 15(3):209-17. PubMed ID: 15943705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis: from science to application.
    Berger ML; Teutsch S
    Med Care; 2005 Jul; 43(7 Suppl):49-53. PubMed ID: 16056009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Australian funding debate on quadrivalent HPV vaccine: a case study for the national pharmaceutical policy.
    Roughead EE; Gilbert AL; Vitry AI
    Health Policy; 2008 Dec; 88(2-3):250-7. PubMed ID: 18468714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voice in political decision-making: the effect of group voice on perceived trustworthiness of decision makers and subsequent acceptance of decisions.
    Terwel BW; Harinck F; Ellemers N; Daamen DD
    J Exp Psychol Appl; 2010 Jun; 16(2):173-86. PubMed ID: 20565202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
    Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
    Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do drug policy makers access research evidence?
    Ritter A
    Int J Drug Policy; 2009 Jan; 20(1):70-5. PubMed ID: 18226519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals.
    Koopmanschap MA; Stolk EA; Koolman X
    Int J Technol Assess Health Care; 2010 Apr; 26(2):198-204. PubMed ID: 20392324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public healthcare resource allocation and the Rule of Rescue.
    Cookson R; McCabe C; Tsuchiya A
    J Med Ethics; 2008 Jul; 34(7):540-4. PubMed ID: 18591290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalised cost-effectiveness analysis: an aid to decision making in health.
    Hutubessy RC; Baltussen RM; Torres-Edejer TT; Evans DB
    Appl Health Econ Health Policy; 2002; 1(2):89-95. PubMed ID: 14619255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness and evidence evaluation as criteria for coverage policy.
    Garber AM
    Health Aff (Millwood); 2004; Suppl Web Exclusives():W4-284-96. PubMed ID: 15451997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the flow of health policy in the United States: self-interest or ignorance?
    Schweitzer SO
    Q Rev Econ Bus; 1990; 30(4):140-7. PubMed ID: 10109704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
    Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of political context upon the health policy process in Pakistan.
    Khan MM; Van den Heuvel W
    Public Health; 2007 Apr; 121(4):278-86. PubMed ID: 17217971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective drug policy: a new approach demonstrated in the Drug Policy Modelling Program.
    Ritter A; Bammer G; Hamilton M; Mazerolle L;
    Drug Alcohol Rev; 2007 May; 26(3):265-71. PubMed ID: 17454015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What influences the transfer of research into health policy and practice? Observations from England and Australia.
    Nutbeam D; Boxall AM
    Public Health; 2008 Aug; 122(8):747-53. PubMed ID: 18561966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Getting evidence into policy: The need for deliberative strategies?
    Flitcroft K; Gillespie J; Salkeld G; Carter S; Trevena L
    Soc Sci Med; 2011 Apr; 72(7):1039-46. PubMed ID: 21419539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of support for cost-utility analysis in the health care reform law: a case of ignorance or political posturing?
    Shaw JW
    Clin Ther; 2010 Jun; 32(6):1091-2. PubMed ID: 20637963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.